Details der Publikation - Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123I-mIBG imaging study

Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123I-mIBG imaging study

Purpose To assess the impact of body mass index (BMI) on cardiac adrenergic derangement, measured by iodine-123 meta-iodobenzylguanidine (123I-mIBG) imaging in heart failure (HF) patients. Overweight and obesity represent relevant health issues, and augmented sympathetic tone has been described in patients with increased BMI. An extensive literature supports that HF-dependent cardiac denervation, measured through mIBG parameters, is an independent predictor of cardiovascular outcomes and mortality. However, the influence of BMI on cardiac mIBG uptake has not been largely investigated. Methods We prospectively enrolled patients with systolic HF, collecting demographic, clinical, echocardiographic data, and mIBG imaging parameters. In order to detect the factors associated with mIBG parameters, a model building strategy, based on the Multivariable Fractional Polynomial algorithm, has been employed. Results We studied 249 patients with systolic HF, mean age of 66.4 ± 10.6 years, and mean left ventricular ejection fraction (LVEF) of 30.7% ± 6.4, undergoing cardiac 123I-mIBG imaging to assess HF severity and prognosis. Seventy-eight patients (31.3%) presented a BMI ≥ 30 kg/$ m^{2} $ and obese patients showed a significant reduction in early heart to mediastinum (H/M) ratio (1.66 ± 0.19 vs. 1.75 ± 0.26; p = 0.008) and a trend to reduction in washout rate (33.6 ± 18.3 vs. 38.1 ± 20.1; p = 0.092) compared with patients with BMI < 30 kg/$ m^{2} $. Multiple regression analysis revealed that BMI, age, and LVEF were significantly correlated with early and late H/M ratios. Conclusions Results of the present study indicate that BMI, together with LVEF and age, is independently correlated with cardiac mIBG uptake in HF patients..

Medienart:	E-Artikel

Erscheinungsjahr:	2019
Erschienen:	2019

Enthalten in:	Zur Gesamtaufnahme - volume:47
Enthalten in:	European journal of nuclear medicine and molecular imaging - 47(2019), 7 vom: 24. Dez., Seite 1713-1721

Sprache:	Englisch

Beteiligte Personen:	Komici, Klara [VerfasserIn] Bencivenga, Leonardo [VerfasserIn] Paolillo, Stefania [VerfasserIn] Gargiulo, Paola [VerfasserIn] Formisano, Roberto [VerfasserIn] Assante, Roberta [VerfasserIn] Nappi, Carmela [VerfasserIn] Marsico, Fabio [VerfasserIn] D’Antonio, Adriana [VerfasserIn] De Simini, Giovanni [VerfasserIn] Cittadini, Antonio [VerfasserIn] Vitale, Dino Franco [VerfasserIn] Cuocolo, Alberto [VerfasserIn] Filardi, Pasquale Perrone [VerfasserIn] Ferrara, Nicola [VerfasserIn] Rengo, Giuseppe [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Body mass index Heart failure I-mIBG imaging Sympathetic nervous system

Anmerkungen:	© Springer-Verlag GmbH Germany, part of Springer Nature 2019

doi:	10.1007/s00259-019-04658-0

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2117781020

Internformat


LEADER	01000naa a22002652 4500
001	OLC2117781020
003	DE-627
005	20230504150151.0
007	cr uuu---uuuuu
008	230504s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00259-019-04658-0 \|2 doi
035			\|a (DE-627)OLC2117781020
035			\|a (DE-He213)s00259-019-04658-0-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
100	1		\|a Komici, Klara \|e verfasserin \|4 aut
245	1	0	\|a Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123I-mIBG imaging study
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer-Verlag GmbH Germany, part of Springer Nature 2019
520			\|a Purpose To assess the impact of body mass index (BMI) on cardiac adrenergic derangement, measured by iodine-123 meta-iodobenzylguanidine (123I-mIBG) imaging in heart failure (HF) patients. Overweight and obesity represent relevant health issues, and augmented sympathetic tone has been described in patients with increased BMI. An extensive literature supports that HF-dependent cardiac denervation, measured through mIBG parameters, is an independent predictor of cardiovascular outcomes and mortality. However, the influence of BMI on cardiac mIBG uptake has not been largely investigated. Methods We prospectively enrolled patients with systolic HF, collecting demographic, clinical, echocardiographic data, and mIBG imaging parameters. In order to detect the factors associated with mIBG parameters, a model building strategy, based on the Multivariable Fractional Polynomial algorithm, has been employed. Results We studied 249 patients with systolic HF, mean age of 66.4 ± 10.6 years, and mean left ventricular ejection fraction (LVEF) of 30.7% ± 6.4, undergoing cardiac 123I-mIBG imaging to assess HF severity and prognosis. Seventy-eight patients (31.3%) presented a BMI ≥ 30 kg/$ m^{2} $ and obese patients showed a significant reduction in early heart to mediastinum (H/M) ratio (1.66 ± 0.19 vs. 1.75 ± 0.26; p = 0.008) and a trend to reduction in washout rate (33.6 ± 18.3 vs. 38.1 ± 20.1; p = 0.092) compared with patients with BMI < 30 kg/$ m^{2} $. Multiple regression analysis revealed that BMI, age, and LVEF were significantly correlated with early and late H/M ratios. Conclusions Results of the present study indicate that BMI, together with LVEF and age, is independently correlated with cardiac mIBG uptake in HF patients.
650		4	\|a Heart failure
650		4	\|a I-mIBG imaging
650		4	\|a Body mass index
650		4	\|a Sympathetic nervous system
700	1		\|a Bencivenga, Leonardo \|4 aut
700	1		\|a Paolillo, Stefania \|4 aut
700	1		\|a Gargiulo, Paola \|4 aut
700	1		\|a Formisano, Roberto \|4 aut
700	1		\|a Assante, Roberta \|4 aut
700	1		\|a Nappi, Carmela \|4 aut
700	1		\|a Marsico, Fabio \|4 aut
700	1		\|a D’Antonio, Adriana \|4 aut
700	1		\|a De Simini, Giovanni \|4 aut
700	1		\|a Cittadini, Antonio \|4 aut
700	1		\|a Vitale, Dino Franco \|4 aut
700	1		\|a Cuocolo, Alberto \|4 aut
700	1		\|a Filardi, Pasquale Perrone \|4 aut
700	1		\|a Ferrara, Nicola \|4 aut
700	1		\|a Rengo, Giuseppe \|0 (orcid)0000-0002-9701-0437 \|4 aut
773	0	8	\|i Enthalten in \|t European journal of nuclear medicine and molecular imaging \|d Springer Berlin Heidelberg, 2002 \|g 47(2019), 7 vom: 24. Dez., Seite 1713-1721 \|h Online-Ressource \|w (DE-627)359787258 \|w (DE-600)2098375-X \|w (DE-576)110279549 \|x 1619-7089 \|7 nnns
773	1	8	\|g volume:47 \|g year:2019 \|g number:7 \|g day:24 \|g month:12 \|g pages:1713-1721
856	4	0	\|u https://dx.doi.org/10.1007/s00259-019-04658-0 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 47 \|j 2019 \|e 7 \|b 24 \|c 12 \|h 1713-1721

Impact of body mass index on cardiac adrenergic derangement in heart failure patients: a 123I-mIBG imaging study

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände